Florida Attorney General James Uthmeier filed a sweeping lawsuit against three insulin manufacturers, three pharmacy benefit managers and several rebate aggregators, accusing them of coordinating a scheme to inflate insulin prices at patients' expense. The complaint names drugmakers Eli Lilly, Novo Nordisk and Sanofi, which together supply more than 90 percent of the world's insulin, alongside pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, which process roughly 80 percent of U.S. prescriptions.
According to News4JAX, the lawsuit also names rebate aggregators Zinc, Ascent and Emisar, alleging that manufacturers inflated published list prices for insulin and related diabetes drugs while paying rebates and fees to pharmacy benefit managers in exchange for preferred formulary placement, per the complaint. Uthmeier said the companies inflated insulin prices and left Florida patients to pay them. Insulin carries both a published list price and a lower net manufacturer price after rebates are factored in.
A Rebate System That Rewards Higher Sticker Prices
The complaint alleges the arrangement allowed manufacturers and pharmacy benefit managers to profit as list prices climbed, even as net prices to manufacturers stayed comparatively low. The state alleges that Lilly returns roughly $210 from every $280 Humalog vial to pharmacy benefit managers as rebates and discounts — about 75 percent of the vial's sticker price. The Federal Trade Commission has separately announced a settlement with Caremark.
The lawsuit's reach extends beyond traditional insulin. It also covers GLP-1 drugs and combination products, including Ozempic, Trulicity, Victoza and Soliqua, per News4JAX's report. The complaint brings two counts under the Florida Deceptive and Unfair Trade Practices Act and one count under the Florida Antitrust Act, and Uthmeier is seeking a permanent injunction, restitution, disgorgement, damages, civil penalties and other relief aimed at protecting Florida families' access to affordable, life-saving medication.
Roughly 2.3 Million Floridians Depend On Insulin
Approximately 2.3 million Florida adults have a diabetes diagnosis, representing about one in 10 adults statewide, the outlet's report notes. Patients with high deductibles or percentage-based coinsurance may be especially exposed to list-price costs.
Part Of A Broader Legal And Regulatory Offensive
This is not Uthmeier's first swing at the PBM industry this year. Less than a month before filing the insulin case, he filed a separate antitrust lawsuit in Polk County Circuit Court accusing Express Scripts and Prime Therapeutics of horizontal price-fixing that reduced pharmacy reimbursement rates on 80 percent of brand-name drugs across Florida, tied to a 2019 collaboration agreement between the two PBMs, as reported by the HMP Global Learning Network. Hoodline covered that filing in earlier PBM price-fixing coverage.
Uthmeier also opened a formal investigation into CVS Health in June, issuing a civil investigative demand examining whether its Caremark subsidiary used anticompetitive tactics to favor CVS-owned retail pharmacies — the company operates roughly 800 stores in Florida — over independent competitors, according to Duane Morris. Federal regulators have already forced structural changes on some of the same companies: the FTC finalized a major settlement with CVS Caremark in July, following an earlier settlement with Express Scripts in February, delinking manufacturer compensation from list prices.
Florida's 2023 Law Set The Stage
Florida already has some guardrails in place. The Prescription Drug Reform Act took effect in May 2023, prohibiting PBM spread pricing, requiring 100 percent pass-through of drug rebates to plan sponsors, and subjecting unlicensed PBMs to daily fines of up to $10,000 starting in 2024, according to Frier Levitt's analysis of the law. That statute set regulatory rules before the state pursued courtroom damages.
Outside Counsel Tied To Campaign Donations
Lawson Huck Gonzalez is representing the state in the case. How any eventual damages would be distributed to affected patients, and how Florida's claims will interact with existing federal settlements and the multidistrict litigation already underway, remain open questions.
